LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier® Therapy will be presented during three sessions at Obesity Week, taking place in Atlanta, Ga., November 11-16, 2013. This event is a combined annual meeting of The Obesity Society (TOS) and The American Society for Metabolic and Bariatric Surgery (ASMBS).
“We are pleased that data on EndoBarrier Therapy will be presented at this important international congress that focuses on the global epidemic of obesity and its complications, including type 2 diabetes,” said David Maggs, M.D., chief medical officer of GI Dynamics. “These data presentations from EndoBarrier users around the globe provide further validation of the growing interest and recognition among physicians about the benefits that EndoBarrier Therapy can provide to people struggling with excess body weight and metabolic control.”
The schedule for EndoBarrier presentations at Obesity Week is as follows:
Date & Time: Thursday, November 14, 2013 from 3 to 5 p.m. EST
Session:
Symposium V/Paper Session VI- Emerging Technologies (ASMBS)
Title:
The Duodenal-Jejunal Bypass Sleeve (EndoBarrier Gastrointestinal Liner)
for Weight Loss and Treatment of Type II Diabetes
Location: A302
Presenters:
Shaneel R. Patel, MBBS/BSc (Hons); Nadey Hakim, M.D. Ph.D; David Hakim;
John Mason
Date & Time: Thursday, November 14, 2013 from 5:30 to 7 p.m. EST
Session:
Poster Session Intervention Studies - Other-Adult
Title:
Duodenal-Jejunal Bypass Liner (DJBL) Induces Favorable Changes on
Hormone Involved in Glucose Homeostasis Regulation in Morbidly Obese
Patients
Location: Exhibit Hall A
Presenter: Alex Escalona,
M.D., Assistant Professor of Surgery, Department of Digestive Surgery,
Pontificia Universidad Católica de Chile, Santiago, Chile
Date & Time: Thursday, November 14, 2013 from 5:30 to 7 p.m. EST
Session:
Poster Session Intervention Studies - Other-Adult
Title: Serum Bile
Acid Concentrations Rise as a Result of Duodenal-Jejunal Bypass Liner
(DJBL) Implantation
Location: Exhibit Hall A
Presenter: Alex
Escalona, M.D., Assistant Professor of Surgery, Department of Digestive
Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile
About EndoBarrier Therapy
EndoBarrier Therapy is a revolutionary, non-surgical, non-pharmaceutical treatment proven to help people living with uncontrolled type 2 diabetes and obesity achieve rapid and dramatic reductions in blood sugar levels, as well as substantial weight loss. EndoBarrier Therapy is a convenient and discreet treatment for people whose diabetes medications are no longer effective, who are at risk for serious health complications and who want to avoid the progression to daily insulin injections. This first-of-its-kind therapy is helping patients around the world fight their battle against type 2 diabetes and obesity while providing a pathway to a healthier lifestyle. For more information, please visit www.endobarrier.com.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.
